Brokers Issue Forecasts for Aytu BioPharma, Inc.’s FY2023 Earnings (NASDAQ:AYTU)
Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings estimates for Aytu BioPharma in a report released on Monday, June 6th. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings per share of ($0.79) for the year.
Several other analysts have also issued reports on AYTU. HC Wainwright reduced their price target on shares of Aytu BioPharma from $24.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, April 28th. Zacks Investment Research raised shares of Aytu BioPharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 25th.
Shares of NASDAQ:AYTU opened at $0.56 on Thursday. The company’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $1.15. Aytu BioPharma has a 12-month low of $0.45 and a 12-month high of $5.97. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.80 and a current ratio of 0.97.
Aytu BioPharma (NASDAQ:AYTU – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($1.38). Aytu BioPharma had a negative net margin of 120.24% and a negative return on equity of 41.97%.
Several institutional investors have recently made changes to their positions in AYTU. Morgan Stanley boosted its stake in shares of Aytu BioPharma by 793.5% in the 3rd quarter. Morgan Stanley now owns 377,922 shares of the company’s stock valued at $1,088,000 after purchasing an additional 335,625 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Aytu BioPharma by 38.4% during the 3rd quarter. Renaissance Technologies LLC now owns 660,604 shares of the company’s stock valued at $1,903,000 after buying an additional 183,235 shares during the last quarter. Marshall Wace LLP bought a new stake in Aytu BioPharma during the 4th quarter valued at $70,000. BlackRock Inc. raised its holdings in Aytu BioPharma by 10.0% during the 4th quarter. BlackRock Inc. now owns 548,724 shares of the company’s stock valued at $741,000 after buying an additional 49,772 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Aytu BioPharma by 16.3% during the 3rd quarter. Geode Capital Management LLC now owns 257,433 shares of the company’s stock valued at $741,000 after buying an additional 35,994 shares during the last quarter. 11.47% of the stock is owned by institutional investors.
About Aytu BioPharma (Get Rating)
Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.
Receive News & Ratings for Aytu BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aytu BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.